Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study

医学 哮喘 呼出气一氧化氮 安慰剂 嗜酸性粒细胞 内科学 过敏 置信区间 恶化 随机对照试验 奥马佐单抗 空气过敏原 欧洲联盟 免疫学 支气管收缩 免疫球蛋白E 过敏原 病理 替代医学 抗体 业务 经济政策
作者
Jonathan Corren,Christopher S. Ambrose,Janet M. Griffiths,Åsa Hellqvist,Andrew Lindsley,Jean‐Pierre Llanos,Gene Colice,Andrew Menzies‐Gow
出处
期刊:Clinical & Experimental Allergy [Wiley]
卷期号:53 (4): 417-428 被引量:18
标识
DOI:10.1111/cea.14256
摘要

Abstract Background Allergic asthma is the most common phenotype among patients with severe asthma. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab significantly reduced the annualized asthma exacerbation rate (AAER) versus placebo in patients with severe, uncontrolled asthma. This exploratory analysis evaluated the efficacy of tezepelumab in NAVIGATOR participants with evidence of severe allergic asthma. Methods Patients (12–80 years old) receiving medium‐ or high‐dose inhaled corticosteroids and ≥ 1 additional controller medication, with or without oral corticosteroids, were randomized to tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks in NAVIGATOR. In this analysis, the AAER, forced expiratory volume in 1 second (FEV 1 ), patient‐reported outcomes (PROs), and type 2 biomarker levels were evaluated in patients grouped by sensitivity to perennial aeroallergens, confirmed symptomatic allergy, and eligibility for omalizumab treatment according to the United States (OMA‐US) and the European Union (OMA‐EU) prescribing information, including subgroups according to baseline blood eosinophil counts and fractional exhaled nitric oxide (FeNO) levels. Results Of 1059 patients who received treatment in NAVIGATOR, 680 (64%) had perennial aeroallergen sensitivity and 318 (30%) had confirmed symptomatic allergy; 379 (36%) and 359 (34%) patients were OMA‐US‐ and OMA‐EU‐eligible, respectively. Tezepelumab reduced the AAER over 52 weeks versus placebo by 58% (95% confidence interval [CI]: 47–67) to 68% (95% CI: 55–77) across these subgroups. Among omalizumab‐eligible patients, AAERs were reduced in patients across baseline blood eosinophil counts and FeNO levels. Tezepelumab improved FEV 1 and PROs, and reduced type 2 biomarkers, versus placebo in patients with and without perennial allergy. Conclusions Tezepelumab was efficacious in patients with severe, uncontrolled asthma with evidence of allergic inflammation, defined by multiple clinically relevant definitions. These findings further support the benefits of tezepelumab in a broad population of patients with severe asthma, including those with severe allergic asthma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
内向芒果完成签到,获得积分10
刚刚
刚刚
min完成签到,获得积分20
1秒前
稳重伊完成签到,获得积分10
2秒前
liangwang发布了新的文献求助10
4秒前
invincible完成签到,获得积分10
4秒前
5秒前
5秒前
5秒前
min发布了新的文献求助10
6秒前
Yolo发布了新的文献求助10
7秒前
mauve完成签到 ,获得积分10
7秒前
CodeCraft应助哇哇哇采纳,获得30
8秒前
李爱国应助聪明小虾米采纳,获得10
8秒前
9秒前
10秒前
Lam发布了新的文献求助10
10秒前
颜回完成签到,获得积分10
10秒前
天真的迎天完成签到,获得积分10
11秒前
在水一方应助开朗艳一采纳,获得10
13秒前
13秒前
达琳完成签到,获得积分20
15秒前
zzt发布了新的文献求助10
16秒前
chen发布了新的文献求助10
16秒前
量子星尘发布了新的文献求助10
16秒前
16秒前
自觉曼岚完成签到,获得积分10
17秒前
18秒前
zmx完成签到 ,获得积分10
18秒前
liangwang完成签到,获得积分10
18秒前
19秒前
善学以致用应助Lam采纳,获得10
20秒前
21秒前
qweasdzxcqwe发布了新的文献求助10
23秒前
VV2VV发布了新的文献求助10
24秒前
陈博文发布了新的文献求助10
25秒前
zzt完成签到,获得积分10
25秒前
ww发布了新的文献求助10
26秒前
万能图书馆应助周游采纳,获得10
28秒前
倩倩发布了新的文献求助10
29秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975661
求助须知:如何正确求助?哪些是违规求助? 3520000
关于积分的说明 11200535
捐赠科研通 3256410
什么是DOI,文献DOI怎么找? 1798247
邀请新用户注册赠送积分活动 877490
科研通“疑难数据库(出版商)”最低求助积分说明 806390